Pauken KE, Wherry EJ. Overcoming T cell exhaustion in infection and cancer. Trends Immunol. 2015;36(4):265–76.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Butt A, Mills K. Immunosuppressive networks and checkpoints controlling antitumor immunity and their blockade in the development of cancer immunotherapeutics and vaccines. Oncogene. 2014;33(38):4623–31.

Article  CAS  PubMed  Google Scholar 

Derakhshani A, et al. From oncogenic signaling pathways to single-cell sequencing of immune cells: changing the landscape of cancer immunotherapy. Molecules. 2021;26(8):2278.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–64.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348(6230):56–61.

Article  CAS  PubMed  Google Scholar 

Park J, Kwon M, Shin E-C. Immune checkpoint inhibitors for cancer treatment. Arch Pharmacal Res. 2016;39:1577–87.

Article  CAS  Google Scholar 

Watanabe R, et al. Immune checkpoint dysfunction in large and medium vessel vasculitis. Am J Physiol-Heart Circ Physiol. 2017;312(5):H1052–9.

Article  PubMed  PubMed Central  Google Scholar 

Pesce S, et al. Cancer immunotherapy by blocking immune checkpoints on innate lymphocytes. Cancers. 2020;12(12):3504.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wykes MN, Lewin SR. Immune checkpoint blockade in infectious diseases. Nat Rev Immunol. 2018;18(2):91–104.

Article  CAS  PubMed  Google Scholar 

Paluch C, et al. Immune checkpoints as therapeutic targets in autoimmunity. Front Immunol. 2018;9:2306.

Article  PubMed  PubMed Central  Google Scholar 

Riva A, Chokshi S. Immune checkpoint receptors: homeostatic regulators of immunity. Hep Intl. 2018;12(3):223–36.

Article  Google Scholar 

Kumar P, Saini S, Prabhakar BS. Cancer immunotherapy with check point inhibitor can cause autoimmune adverse events due to loss of Treg homeostasis. Sem Cancer Biol. 2020. https://doi.org/10.1016/j.semcancer.2019.01.006.

Article  Google Scholar 

Dougan M. Checkpoint blockade toxicity and immune homeostasis in the gastrointestinal tract. Front Immunol. 2017;8:1547.

Article  PubMed  PubMed Central  Google Scholar 

Abdeladhim M, Karnell JL, Rieder SA. In or out of control: modulating regulatory T cell homeostasis and function with immune checkpoint pathways. Front Immunol. 2022;13:1033705.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Marshall N, et al. Antitumor T-cell homeostatic activation is uncoupled from homeostatic inhibition by checkpoint blockade. Cancer Discov. 2019;9(11):1520–37.

Article  CAS  PubMed  PubMed Central  Google Scholar 

He X, Xu C. Immune checkpoint signaling and cancer immunotherapy. Cell Res. 2020;30(8):660–9.

Article  PubMed  PubMed Central  Google Scholar 

Li B, Chan HL, Chen P. Immune checkpoint inhibitors: basics and challenges. Curr Med Chem. 2019;26(17):3009–25.

Article  CAS  PubMed  Google Scholar 

Van Mol P, et al. Immune checkpoint biology in health & disease: immune checkpoint biology and autoimmunity in cancer patients. Int Rev Cell Mol Biol. 2024;382:181–206.

Article  PubMed  Google Scholar 

Hamers-Casterman C, et al. Naturally occurring antibodies devoid of light chains. Nature. 1993;363(6428):446–8.

Article  CAS  PubMed  Google Scholar 

Kim J, Maharjan R, Park J. Current trends and innovative approaches in cancer immunotherapy. AAPS PharmSciTech. 2024;25(6):168.

Article  PubMed  Google Scholar 

Keizer RJ, et al. Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet. 2010;49:493–507.

Article  CAS  PubMed  Google Scholar 

Pendley C, Schantz A, Wagner C. Immunogenicity of therapeutic monoclonal antibodies. Curr Opin Mol Ther. 2003;5(2):172–9.

CAS  PubMed  Google Scholar 

Wang W, Wang E, Balthasar J. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 2008;84(5):548–58.

Article  CAS  PubMed  Google Scholar 

Farid SS. Process economics of industrial monoclonal antibody manufacture. J Chromatogr B. 2007;848(1):8–18.

Article  CAS  Google Scholar 

Muyldermans S, Cambillau C, Wyns L. Recognition of antigens by single-domain antibody fragments: the superfluous luxury of paired domains. Trends Biochem Sci. 2001;26(4):230–5.

Article  CAS  PubMed  Google Scholar 

Sun S, et al. Nanobody: a small antibody with big implications for tumor therapeutic strategy. Int J Nanomed. 2021;16:2337–56.

Article  Google Scholar 

Bao G, et al. Nanobody: a promising toolkit for molecular imaging and disease therapy. EJNMMI Res. 2021;11:1–13.

Article  Google Scholar 

Zhang F, et al. Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade. Cell Discov. 2017;3(1):1–12.

Article  Google Scholar 

Sun X, et al. PD-L1 nanobody competitively inhibits the formation of the PD-1/PD-L1 complex: comparative molecular dynamics simulations. Int J Mol Sci. 2018;19(7):1984.

Article  PubMed  PubMed Central  Google Scholar 

Wan R, et al. Screening and antitumor effect of an anti-CTLA-4 nanobody. Oncol Rep. 2018;39(2):511–8.

CAS  PubMed  Google Scholar 

Babamohamadi M, et al. Anti-CTLA-4 nanobody as a promising approach in cancer immunotherapy. Cell Death Dis. 2024;15(1):17.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lee CS, et al. Novel antibodies targeting immune regulatory checkpoints for cancer therapy. Br J Clin Pharmacol. 2013;76(2):233–47.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schlöder J, et al. Boosting regulatory T cell function for the treatment of autoimmune diseases–that’s only half the battle! Front Immunol. 2022;13:973813.

Article  PubMed  PubMed Central  Google Scholar 

Goswami TK, et al. Regulatory T cells (Tregs) and their therapeutic potential against autoimmune disorders–advances and challenges. Hum Vaccin Immunother. 2022;18(1):2035117.

Article  PubMed  PubMed Central